Epidemiology of squamous cell carcinoma;Epidemiologie van het plaveiselcelcarcinoom

Nederlands Tijdschrift voor Dermatologie en Venereologie

Volumn 16, Issue 9, 2006, Pages 380-383

  'T Hoen, M ^a   Nijsten, T E C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Incidence; Risk factors; Squamous cell carcinoma

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONFERENCE PAPER; HUMAN; METASTASIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

EID: 33751190280     PISSN: 09258604     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. LeBoit PE, Burg G, Weedon D, Sarasin A. WHO Classification of Tumours. Pathology and genetics of tumours of the skin. Lyon: IARC Press, 2005.
2. Cassarino DS, DeRienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part Two. J Cutan Pathol 2006;33:261-79.
3. Koh D, Wang H, Lee J, Chia KS, Lee HP, Goh CL. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry data 1968-97. Br J Dermatol 2003;148:1161-6.
4. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999;135:781-6.
5. Katalanic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003;149:1200-6.
6. http://www.ikcnet.nl/page.php?id=41
7. Holme SA, Malinkovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000;143:1224-9.
8. Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer EV. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005;53:320-8.
9. Levi F, Te VC, Randimbison L, Erler G, La Vecchia C. Trends in skin cancer incidence in Vaud: an update, 1976-1998. Eur J Cancer Prev 2000;10:371-3.
10. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona. J Am Acad Dermatol 2001;45:528-36.
11. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. MJA 2006;184:6-10.
12. Vries E de, Poll-Franse LV van de, Louwman WJ, Gruijl FR de, Coebergh JWW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005;152:481-8.
13. Dwyer T, Stankovich JM, Blizzard L, et al. Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? Am J Epidemiol 2004;159:826-33.
14. Marshall SE, Bordea C, Haldar NA, et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney International 2000;58:2186-93.
15. Struijk L, Schegget J ter, Bouwes Bavinck JN, Feltkamp MCW. Humaan papillomavirus in de etiologie van huidkanker. Ned Tijdschr Geneeskd 2005;149:518-22.
16. Armstrong B, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63:8-18.
17. Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer 2006;94:743-51.
18. Levine JA, Sorace M, Spencer J, Siegel DM. The indoor UV tanning industry: a review of skin cancer risk, health benefit claims, and regulation. J Am Acad Dermatol 2005;53:1038-44.
19. Karagas MR, Nelson HH, Sehr P, et al. Human papilloma-virus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Am 2006;98:389-95.
20. Hertog SAE de, Wensveen CAH, Bastiaens MT, et al. Relation between smoking and skin cancer. J Clin Oncol 2001;19:231-8.
21. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006;54:189-206.
22. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002;138:758-63.
23. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498-504.
24. Caforio ALP, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000;102:222-7.
25. Perera GK, Child FJ, Heaton N, O'Grady J, Higgins EM. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 2006;154:868-72.
26. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 2005;11:1100-6.
27. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: follow-up study. Transplantation 1996;61:715-21.
28. Fortina AB, Piaserico S, Caforio ALP, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004;140:1079-85.
29. Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006;154:395-400.
30. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. Arch Dermatol 2006;142:712-8.
31. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003;121:252-8.
32. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 2001;358:1042-5.
33. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644-50.
34. Butler GJ, Neale R, Green AC, Pandeya N, Whitman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005;53:966-72.
35. Clayman GL, Lee JJ, Holsinger C, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005;23:759-65.
36. Rowe DE, Caroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976-90.
37. Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology 1994;189:52-4.
38. Griffiths RW, Feeley K, Survana SK. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg 2002;55:287-92.
39. Mulen JT, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006;13:902-9.
40. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 2002;28:268-73.